Botulism

Global Botulinum Toxin Market (2020 to 2024) - Size & Forecasts with Impact Analysis of COVID-19 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 6, 2021
Surgery, Health, Other Health, Drugs, Botulism, Toxins, Botulinum toxin, Neurotoxins, Toxicology, Market segmentation, Market

The "Global Botulinum Toxin Market: Size & Forecasts with Impact Analysis of COVID-19 (2020-2024 Edition)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Botulinum Toxin Market: Size & Forecasts with Impact Analysis of COVID-19 (2020-2024 Edition)" report has been added to ResearchAndMarkets.com's offering.
  • The report provides an in-depth analysis of the global botulinum toxin market with detailed analysis of the actual and the expected market size along with the market size of each market segment on the basis of application, products as well as regional.
  • The report provides a detailed regional analysis of the US, Europe, Japan, Asia (excluding Japan), Korea and China for the botulinum toxin market.
  • Regional analysis includes the market share of each region or country and the actual and forecasted market size of the botulinum toxin market along with the market segments of the aforementioned regions.

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, December 21, 2020
Biotechnology, Pharmaceutical, Health, Drugs, Plastic surgery, Toxins, Botulinum toxin, Botulism, Neurotoxins, Toxicology

Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.

Key Points: 
  • Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • Revance has also partnered with Viatris to develop a biosimilar to BOTOX, which would compete in the existing short-acting neuromodulator marketplace.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    RHA resilient hyaluronic acid and RHA are trademarks of TEOXANE SA.

FDA Approves Pediatric Indication for XEOMIN® (incobotulinumtoxinA) for the Treatment of Chronic Sialorrhea

Retrieved on: 
Monday, December 21, 2020
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Drugs, Medical specialties, Health care, Botulinum toxin, Botulism, Neurotoxins, Toxins, Priority review, Food and Drug Administration

XEOMIN is the first and only FDA-approved neuromodulator with this indication and was granted a priority review designation upon acceptance by the FDA.

Key Points: 
  • XEOMIN is the first and only FDA-approved neuromodulator with this indication and was granted a priority review designation upon acceptance by the FDA.
  • Pediatric patients living with chronic sialorrhea have suffered with this debilitating condition without a viable long-acting treatment option, said Kevin OBrien, President of North America, Merz Therapeutics.
  • GICS scores were comparable among patients ages 2 5 years, all of whom received XEOMIN treatment and not placebo throughout the study.
  • The most common side effects of XEOMIN in adults with chronic sialorrhea include:
    The most common side effects of XEOMIN in children 2 to 17 years of age with chronic sialorrhea include:

Revance Reports Positive Efficacy and Duration Results from Phase 2 Upper Facial Lines Study

Retrieved on: 
Thursday, December 17, 2020
Cosmetics, Retail, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Drugs, Plastic surgery, Toxins, Botulinum toxin, Botulism, Neurotoxins, Pharmacology, Dose-ranging study, Frown, Dosing

This full upper face data complements our already reported results from individual dose-ranging studies, and further expands the body of knowledge on our next-generation neuromodulator.

Key Points: 
  • This full upper face data complements our already reported results from individual dose-ranging studies, and further expands the body of knowledge on our next-generation neuromodulator.
  • Interim Week 4 data from the Phase 2a studies in forehead lines and crows feet were used in the final design of this upper facial lines Phase 2 study to optimize dosing and injection patterns.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

DGAP-News: New Worldwide Patents Issued on Discovery for Botulinum NeuroToxin in Combination with Silver Nano Particles Creating Extraordinary Outcomes

Retrieved on: 
Wednesday, December 16, 2020
Medical specialties, Drugs, Clinical medicine, Sexually transmitted diseases and infections, Botulism, Viral diseases, Neurotoxin, Herpes simplex virus, Botulinum toxin, Nano, Herpes labialis

Willoughby and Dr. Keith W. Moeller have been granted and issued numerous patents worldwide - including in Asia, Europe, and now the United States - on the combination and utilization of Nano-Silver with various Botulinum NeuroToxins ("BONTs").

Key Points: 
  • Willoughby and Dr. Keith W. Moeller have been granted and issued numerous patents worldwide - including in Asia, Europe, and now the United States - on the combination and utilization of Nano-Silver with various Botulinum NeuroToxins ("BONTs").
  • There were also notable anti-viral effects in patients with cold sores (HSV-1), and none of these patients experienced any adverse events.
  • We also have a completed IRB-sponsored Phase-2 human ingestion study - the largest of its kind ever performed with a Nano-Silver compound.
  • 16.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.

Global Cosmetic Surgery and Services Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 15, 2020
Health, General Health, Drugs, Botulinum toxin, Botulism, Neurotoxins, Toxins, Medical specialties, Cosmetic, Cosmetic surgery in Australia, Mauricio de Maio

The most common use of this toxin is in the treatment of painful muscle spasm and cosmetic treatment.

Key Points: 
  • The most common use of this toxin is in the treatment of painful muscle spasm and cosmetic treatment.
  • Botox and Dysport are the commercial names of the botulinum toxin.
  • North America dominates the cosmetic surgery and services market, owing to the rising number of people focusing on the external aesthetics and the improvements that are being done in cosmetic procedures.
  • Currently, people in the United States are spending more money on cosmetics and are eager to adopt novel cosmetic treatments.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Evolus, Inc. (EOLS)

Retrieved on: 
Friday, December 11, 2020
Legal, Professional services, Drugs, Botulism, Toxins, Botulinum toxin, Neurotoxins, Toxicology

On July 6, 2020, the U.S. International Trade Commission (ITC) issued its Final Initial Determination in a case alleging that Evolus stole certain trade secrets to develop Jeuveau.

Key Points: 
  • On July 6, 2020, the U.S. International Trade Commission (ITC) issued its Final Initial Determination in a case alleging that Evolus stole certain trade secrets to develop Jeuveau.
  • The ITC Judge found that Evolus misused the botulinum toxin strain as well as the manufacturing processes that led to its development and manufacture.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Botulinum Toxin Market - Growth, Trends, and Forecasts (2020 - 2025)

Retrieved on: 
Thursday, November 19, 2020
Drugs, Botulinum toxin, Neurotoxins, Toxins, Medical specialties, Botulism, Management of strabismus

NEW YORK, Nov. 19, 2020 /PRNewswire/ -- The botulinum toxin market is primarily driven by rising aesthetic consciousness and a number of non-invasive cosmetic procedures.

Key Points: 
  • NEW YORK, Nov. 19, 2020 /PRNewswire/ -- The botulinum toxin market is primarily driven by rising aesthetic consciousness and a number of non-invasive cosmetic procedures.
  • There is a rising demand for aesthetic appearance among the individuals that have created a subsequent demand for botulinum toxin procedures around the world.
  • Moreover, the effects of the botulinum toxin take about two weeks to develop and usually last three to four months fully.
  • There is also increased competition in the US botulinum toxin market that is set to increase with the launch of Jeuveau.

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

Retrieved on: 
Tuesday, November 17, 2020
Health, Surgery, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Clinical trials, Anatomy, Branches of biology, Drugs, Botulinum toxin, Botulism, Neurotoxins, Placebo-controlled study, Dose-ranging study, Ptosis, Eyelid

At all doses tested in the trial, Dysport had a strong safety profile, including very few cases of eyelid ptosis.

Key Points: 
  • At all doses tested in the trial, Dysport had a strong safety profile, including very few cases of eyelid ptosis.
  • The multicenter, randomized, dose-ranging, double-blind, placebo-controlled Phase 2 study enrolled 401 subjects ages 18 to 65 with moderate to severe glabellar lines at maximum frown.
  • Favorable results were achieved for all doses in the secondary objectives, including a 1-grade improvement and subject satisfaction throughout the study duration.
  • This phase 2 study underscores our commitment to bring efficacious products and long-lasting results to customers, said Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma.

Aesthetic Innovations Partners with Merz Aesthetics to Launch National Xeomin® (incobotulinumtoxinA) Campaign

Retrieved on: 
Thursday, November 5, 2020
Articles, Drugs, Visual arts, Botulinum toxin, Botulism, Neurotoxins, Toxins, Merz, Kurt Schwitters, Aesthetics

BOISE, Idaho, Nov. 5, 2020 /PRNewswire/ --Aesthetic Innovations; announced a working relationship with Merz Aesthetics on one of aesthetic medicine's most significant recent initiatives: a national campaign to introduce a new celebrity spokesperson for their Xeomin product line, a new generation neurotoxin.

Key Points: 
  • BOISE, Idaho, Nov. 5, 2020 /PRNewswire/ --Aesthetic Innovations; announced a working relationship with Merz Aesthetics on one of aesthetic medicine's most significant recent initiatives: a national campaign to introduce a new celebrity spokesperson for their Xeomin product line, a new generation neurotoxin.
  • "Leading brands like Merz, as well as their selective clients, are looking for scalable video personalization and extreme simplicity.
  • At Merz Aesthetics, we are a medical aesthetics business with a long history of empowering health care professionals, patients and employees to live every day with confidence.
  • Merz Aesthetics is part of Merz Group, a family owned company founded in 1908 and based in Frankfurt, Germany.